Can I read Commentary: Old Data Provide New Insights Into the Therapeutic Benefit of Adjuvant Chemotherapy in Non-Small Cell Lung Cancer on EtoBox?

Commentary: Old Data Provide New Insights Into the Therapeutic Benefit of Adjuvant Chemotherapy in Non-Small Cell Lung Cancer by Kyle G. Mitchell; Mara B. Antonoff is a Medicine article available to read on EtoBox.

What is Commentary: Old Data Provide New Insights Into the Therapeutic Benefit of Adjuvant Chemotherapy in Non-Small Cell Lung Cancer about?

The pivotal Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis demonstrated a clear, albeit modest, survival benefit associated with the administration of adjuvant chemotherapy among patients with resected non-small cell lung cancer (NSCLC). 1 Despite publication of these data almost 15 years ago, adjuvant systemic therapy remains grossly underutilized. 2 Although the reasons for this discordance are complex and likely multifactorial, it is at least to some degree due to the small magnitude of the identified overall survival benefit.In this issue of Seminars, Toubat et al. report a post hoc subgroup analysis of the JBR10 trial 4 that randomized NSCLC patients following complete resection to receipt of cisplatin and vinorelbine or observation alone. In order to examine the therapeutic effect of adjuvant chemotherapy within a patient cohort most likely to derive benefit, the authors restricted their analysis to the subgroup of patients with pN1 disease. In doing so, they observed a dramatic improvement in 5-year overall (OS; 61.4% vs 41.0%; HR 0.65) and recurrence-free survival (RFS; 56.2% vs 39.9%; HR 0.58) among patients who received adjuvant chemotherapy that persisted after

Who reads Commentary: Old Data Provide New Insights Into the Therapeutic Benefit of Adjuvant Chemotherapy in Non-Small Cell Lung Cancer?

Author

Kyle G. Mitchell; Mara B. Antonoff

Publisher

Elsevier BV

Published

2022

Language

EN

Field

Medicine (Health Sciences)